Should You Scoop Up Shares of 23andMe?

: ME | 23andMe Holding Co. Class A Common Stock News, Ratings, and Charts

ME – 23andMe (ME) saw its shares slump in price after it reported its fourth-quarter earnings results last month. However, given the company’s multiple FDA authorizations for over-the-counter genetic health risk reports, would it be worth scooping up its shares now? Read on, let’s find out.

23andMe Holding Co. (ME) in Sunnyvale, Calif., is a renowned consumer genetics and research company. As the only company with several FDA authorizations for genetic health risk reports, 23andMe has pioneered direct access to genetic information. The company has built the world’s largest crowdsourcing platform for genetic research, with 80% of its customers signing in.

The company’s shares are down 72.9% in price over the past year and 33.5% over the past three months to close yesterday’s trading session at $2.70. 

The genetic-testing firm saw its loss increase in its fiscal fourth quarter and published guidance that implies the loss will increase. The company stated that it prioritizes cash burn over sales growth within its personal genomic service and telemedicine consumer businesses.

Here is what could shape ME’s performance in the near term:

Inadequate Financials

ME’s revenue increased 13.5% year-over-year to $100.56 million for the fourth quarter, ended March 31, 2022. Its loss from operations grew 3.5% from the prior-year quarter to $69.45 million. The company’s net loss grew 3.8% from its year-ago value to $69.54 million. And its loss per share amounted to $0.16. In addition, its net cash used in operating activities surged 124.7% year-over-year to $166.83 million.

Poor Profitability

ME’s 0.34% trailing-12-month asset turnover ratio is 4.7% lower than the 0.36% industry average. Its 48.9% trailing-12-month gross profit margin is 12.1% lower than the 55.6% industry average. Also, its trailing-12-month ROA, ROC, and net income margin are negative 18.9%, 21.9%, and 79.9%, respectively.

POWR Ratings Reflect Bleak Outlook

ME has an overall D rating, which equates to Sell in our proprietary POWR Ratings system. The POWR ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

Our proprietary rating system also evaluates each stock based on eight distinct categories. ME has a D for Stability and Quality. The Stability grade represents higher stock volatility than its peers. In addition, the company’s poor profitability is consistent with the Quality grade.

Among the 52 stocks in the D-rated Medical – Diagnostic/Research industry, ME is ranked #40.

Beyond what I have stated above, you can view ME ratings for Growth, Value, Momentum, and Sentiment here.

Click here to checkout our Healthcare Sector Report for 2022

Bottom Line

ME’s deteriorating fundamental performance could raise investors’ concerns over its prospects. In addition, analysts expect its EPS to decline 45.5% in the next quarter (ending Sept. 30, 2022) and 7.8% in the current year. Furthermore, the stock is currently trading below its 50-day and 200-day moving averages of $3.17 and $6.34, respectively, indicating a downtrend. So, we think the stock is best avoided now.

How Does 23andM Holding Co. (ME) Stack Up Against its Peers?

While ME has an overall D rating, one might want to consider its industry peers, Global Cord Blood Corporation (CO), Qiagen N.V. (QGEN), and Agilent Technologies Inc. (A), which have an overall A (Strong Buy) rating.


ME shares were unchanged in premarket trading Monday. Year-to-date, ME has declined -59.46%, versus a -13.29% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
MEGet RatingGet RatingGet Rating
COGet RatingGet RatingGet Rating
QGENGet RatingGet RatingGet Rating
AGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

History Lessons Say Stocks About to Head Lower Again

Yes, history has a way of repeating itself. Like how periods of high inflation are followed by recessions and bear markets time and time again. Or how periods of high stock valuations often lead to extended bear markets like 2000 to 2003…and yes that may be repeating now. Before you believe that the next bull market has emerged you may want to read this article to appreciate why the odds point to more downside ahead.

:  |  News, Ratings, and Charts

The 3 Top Aerospace and Defense Stocks to Buy Now

The U.S. aerospace and defense industry is evolving, supported by lucrative fiscal investments and rapid defense technology advancement. Moreover, given the growing tension between China and Taiwan, it could be wise to add quality aerospace and defense stocks, Lockheed Martin (LMT), L3Harris Technologies (LHX), and Raytheon Technologies Corp. (RTX) to your portfolio now. Continue reading…

:  |  News, Ratings, and Charts

After the Bear Market Rally What Comes Next?

The stock market is in the midst of an impressive and blistering rally. From the mid-June lows, the S&P 500 (SPY) is up 14%, while the Nasdaq Composite is closing in on a 20% gain. Some of the factors behind this rally are extreme bearish positioning, better than expected economic data, marginally positive news on inflation, and odds of a 'soft landing' that have increased from implausible to 'pretty unlikely'. In today's commentary, I want to reiterate why I continue to see this as a 'bear market rally' rather than the start of a new bull market. Then, I want to provide some more insight on the thinking behind today's trade alert. We will conclude with an overview of the portfolio. and a couple of quick notes from my recent visit to Iceland. Read on below to find out more…

:  |  News, Ratings, and Charts

2 Momentum Stocks Crushing the Bear Market

Valero Energy (VLO) and Shell (SHEL) have maintained strong momentum amid the highly uncertain market conditions. With recession fears expected to keep the market under pressure in the near term, it could be wise to buy these stocks now to benefit from their momentum, which might continue for some time based on their fundamental strength irrespective of the market conditions. Read on…

:  |  News, Ratings, and Charts

After the Bear Market Rally What Comes Next?

The stock market is in the midst of an impressive and blistering rally. From the mid-June lows, the S&P 500 (SPY) is up 14%, while the Nasdaq Composite is closing in on a 20% gain. Some of the factors behind this rally are extreme bearish positioning, better than expected economic data, marginally positive news on inflation, and odds of a 'soft landing' that have increased from implausible to 'pretty unlikely'. In today's commentary, I want to reiterate why I continue to see this as a 'bear market rally' rather than the start of a new bull market. Then, I want to provide some more insight on the thinking behind today's trade alert. We will conclude with an overview of the portfolio. and a couple of quick notes from my recent visit to Iceland. Read on below to find out more…

Read More Stories

More 23andMe Holding Co. Class A Common Stock (ME) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ME News